FAQ: Quantum BioPharma Ltd. Legal Victory and Company Overview
Summary
What was the outcome of Quantum BioPharma’s legal dispute with its former CEO?
The Court of Appeal for Ontario fully dismissed a reconsideration motion filed by former CEO Dr. Raza Bokhari, who was terminated for cause in 2021, resulting in over C$3 million in awarded costs to Quantum BioPharma.
Why is the legal victory significant for Quantum BioPharma?
This victory reinforces Quantum BioPharma’s stance in the dispute, securing financial compensation and allowing the company to focus on its core mission of developing treatments for neurodegenerative and metabolic disorders.
How much has Quantum BioPharma been awarded in costs from the legal dispute?
Quantum BioPharma has been awarded a total of over C$3 million in costs, including approximately C$2.81 million plus interest from an arbitration and additional court-awarded costs.
What is Quantum BioPharma’s focus area in biopharmaceuticals?
Quantum BioPharma focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, with drug candidates in various stages of development.
What is Lucid-MS, and who is developing it?
Lucid-MS is a patented new chemical entity developed by Quantum BioPharma’s subsidiary, Lucid Psycheceuticals Inc., shown to prevent and reverse myelin degradation in preclinical models, targeting multiple sclerosis.
What is UNBUZZD, and how is Quantum BioPharma involved?
UNBUZZD is a product invented by Quantum BioPharma, with its OTC version spun out to Celly Nutrition Corp. Quantum BioPharma retains a 25.71% ownership in Celly Nutrition and receives royalty payments from sales.
Where can investors find the latest news and updates about Quantum BioPharma?
Investors can find the latest news and updates relating to QNTM in the company’s newsroom at https://ibn.fm/QNTM.
What are the implications of the legal dispute for Quantum BioPharma’s future?
The dismissal of the motion and the financial awards allow Quantum BioPharma to continue its research and development efforts without the distraction of ongoing legal disputes, focusing on its innovative treatments.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 123508